Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Gilead Sciences
GILD
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$83.89
0.84
1.01%
At Close: -
$84.05
0.16
0.19%
After Hours: 4:47 PM EDT
15 minutes delayed
Get Report
Comment
The dividend Ex-Date was 5 days ago
Gilead Sciences (GILD) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Neutral on Gilea...
Benzinga Newsdesk
Friday, September 13, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Benzinga Insights
Marengo Therapeutics Enters Clinical Study Co...
Benzinga Newsdesk
Thursday, September 12, 2024
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Vandana Singh
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF?
Zacks
What the Options Market Tells Us About Gilead Sciences
Benzinga Insights
Gilead shares are trading higher after the co...
Benzinga Newsdesk
Gilead Announces Results Of Interim Analysis ...
Benzinga Newsdesk
Wednesday, September 11, 2024
Piper Sandler Maintains Overweight on Gilead ...
Benzinga Newsdesk
Tuesday, September 10, 2024
Gilead Sciences shares are trading higher aft...
Benzinga Newsdesk
Gilead Sciences And Genesis Therapeutics Anno...
Benzinga Newsdesk
Monday, September 09, 2024
AstraZeneca Says Datopotamab Deruxtecan Showe...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Neutral on Gilea...
Benzinga Newsdesk
Friday, September 06, 2024
Peering Into Gilead Sciences's Recent Short Interest
Benzinga Insights
Thursday, September 05, 2024
Gilead To Present New Trodelvy Data At The IA...
Benzinga Newsdesk
Wednesday, September 04, 2024
Unveiling 10 Analyst Insights On Gilead Sciences
Benzinga Insights
RBC Capital Maintains Sector Perform on Gilea...
Benzinga Newsdesk
Tuesday, September 03, 2024
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Surbhi Jain
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
Benzinga Insights
Avenzo Therapeutics Announces Clinical Study ...
Benzinga Newsdesk
Tuesday, August 27, 2024
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Benzinga Insights
Thursday, August 22, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Benzinga Insights
Tuesday, August 20, 2024
Peering Into Gilead Sciences's Recent Short Interest
Benzinga Insights
Friday, August 16, 2024
Pantherx Rare Partnering With Gilead Sciences...
Benzinga Newsdesk
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
Vandana Singh
Thursday, August 15, 2024
Truist Securities Maintains Hold on Gilead Sc...
Benzinga Newsdesk
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
Vandana Singh
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
Benzinga Insights
Needham Reiterates Hold on Gilead Sciences
Benzinga Newsdesk
Wednesday, August 14, 2024
FDA Approves Gilead's Livdelzi For Primary Bi...
Benzinga Newsdesk
Friday, August 09, 2024
RBC Capital Maintains Sector Perform on Gilea...
Benzinga Newsdesk
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Vandana Singh
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
Piero Cingari
Cantor Fitzgerald Reiterates Neutral on Gilea...
Benzinga Newsdesk
Gilead Sciences shares are trading lower. The...
Benzinga Newsdesk
BMO Capital Maintains Outperform on Gilead Sc...
Benzinga Newsdesk
Thursday, August 08, 2024
Gilead Sciences Raises FY24 Adj EPS Forecast ...
Benzinga Newsdesk
Gilead Sciences Q2 2024 Adj. EPS $2.01 Beats ...
Benzinga Newsdesk
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Piero Cingari
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
Shanthi Rexaline
Tuesday, August 06, 2024
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Friday, August 02, 2024
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Chris Katje
Tuesday, July 30, 2024
Gilead Sciences's Options Frenzy: What You Need to Know
Benzinga Insights
Monday, July 29, 2024
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Avi Kapoor
Friday, July 26, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, July 25, 2024
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
Piero Cingari
This Is What Whales Are Betting On Gilead Sciences
Benzinga Insights
Gilead Sciences shares are trading higher aft...
Benzinga Newsdesk
Gilead Sciences Presents New 5-Year Data Rein...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch